Notice2024-24565
Government Owned Inventions Available for Licensing/Collaboration: Tixocortol for the Prevention or Treatment of SARS-CoV-2 and Other Coronaviruses
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 23, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the licensing and collaboration opportunity for the inventions listed below, which are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally- funded research and development.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 205 (Wednesday, October 23, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 205 (Wednesday, October 23, 2024)]
[Notices]
[Pages 84610-84611]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-24565]
[[Page 84610]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for Licensing/
Collaboration: Tixocortol for the Prevention or Treatment of SARS-CoV-2
and Other Coronaviruses
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute (NCI), an institute of the
National Institutes of Health (NIH), Department of Health and Human
Services (HHS), is giving notice of the licensing and collaboration
opportunity for the inventions listed below, which are owned by an
agency of the U.S. Government and are available for licensing in the
U.S. to achieve expeditious commercialization of results of federally-
funded research and development.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing/
collaboration opportunity should be directed to: Suna Gulay French,
Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center,
Email: <a href="/cdn-cgi/l/email-protection#added8c3cc83cad8c1ccd4edc3c4c583cac2db"><span class="__cf_email__" data-cfemail="daa9afb4bbf4bdafb6bba39ab4b3b2f4bdb5ac">[email protected]</span></a> or Phone: 240-276-7424.
SUPPLEMENTARY INFORMATION: The recent COVID-19 pandemic led to millions
of deaths worldwide--presenting an urgent need to develop vaccines and
therapeutics against SARS-CoV-2 infections. Although vaccines saved
lives by preventing severe disease progression, there remains a need
for additional therapeutics that may prevent and/or treat coronavirus
infections. The return of symptoms after the use of certain COVID-19
medications demonstrate the need for additional treatment options.
Investigators at the NCI have found a previously approved
corticosteroid, tixocortol, to be an inhibitor of the homodimeric main
protease (Mpro) of SARS-CoV-2 at an allosteric site of inhibition,
cysteine residue 300 (Cys300). Coronaviruses rely on Mpro for
proteolytic processing to produce mature forms of the virus--deeming
Mpro an excellent target to inhibit SARS-CoV-2 infection. Tixocortol
may also be useful against SARS-CoV-1 due to the conservation of Cys300
and in future coronavirus outbreaks. Tixocortol displays inhibitory
effect against Mpro when added to cell culture up to 18 hours prior to
coronavirus infection, indicating possible preventive use. Tixocortol
pivalate was previously manufactured as a spray and would be easy to
apply before entering crowded areas for prevention.
This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part
404.
NIH Reference Number: E-228-2023-0.
Potential Commercial Applications:
<bullet> Treatment of SARS-CoV-2 and SARS-CoV-1 infections
<bullet> Preventive of SARS-CoV-2 and SARS-CoV-1 infections and
symptoms
<bullet> Therapeutic and preventive use against other coronaviruses and
respiratory viruses where the allosteric site of inhibition is
conserved.
Competitive Advantages:
<bullet> Previously developed corticosteroid with a good safety profile
<bullet> Non-toxic and non-immunosuppressive
<bullet> Nasal delivery
<bullet> Potential use against other coronaviruses
<bullet> Inhibitory effect against SARS-CoV-2 main protease in cell
culture up to 18 hours prior to viral infection
Patent Status: US Provisional Application 65/599,446 filed on
November 15, 2023.
Therapeutic Area(s): Infectious Diseases, immune, or inflammation.
Development Stage: Discovery.
[[Page 84611]]
[GRAPHIC] [TIFF OMITTED] TN23OC24.006
Dated: October 18, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2024-24565 Filed 10-22-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 23, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.